Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 15/20 | 0.43 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338495 | 0.89 | GRM2 (0.51) | GRM2GRM7SPHK2 | |
| SCHEMBL1338498 | 0.89 | GRM2 (0.51) | GRM2GRM7SPHK2 | |
| SCHEMBL1339262 | 0.89 | GRM2 (0.51) | GRM2GRM7SPHK2 | |
| SCHEMBL1339105 | 0.86 | GRM2 (0.40) | GRM2GRM7SPHK2 | |
| SCHEMBL1339289 | 0.86 | GRM2 (0.40) | GRM2GRM7SPHK2 | |
| SCHEMBL1339104 | 0.86 | GRM2 (0.40) | GRM2GRM7SPHK2 | |
| SCHEMBL1339310 | 0.77 | GRM2 (0.41) | GRM2DGAT1BRD9 | |
| SCHEMBL1339018 | 0.77 | GRM2 (0.51) | GRM2GRM7 | |
| SCHEMBL1339020 | 0.77 | GRM2 (0.51) | GRM2GRM7 | |
| SCHEMBL1339054 | 0.74 | GRM2 (0.54) | GRM2GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697689-B2 | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM1, GRM5 | GRM2 1/4885GRM7 10/4885DGAT1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.